High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer

Inclusion criteria Work-unit 1 * age \< 75 years of age, with histologically proven invasive adenocarcinoma of the prostate * a risk of equal or more than 5% of lymph node metastasis (intermediate to high risk disease), according to the Briganti nomogram (1) * scheduled to undergo radical prostatectomy with extended lymph node dissection Work-unit 2 * histologically proven diagnosis of prostate cancer * biochemical relapse (two consecutive PSA≥0.2 ng/ml) of prostate cancer following radical local prostate treatment * WHO performance state 0-1 * age \> 18 years old Exclusion criteria Work-unit 1 * involvement of pelvic lymph nodes assessed by multi-parametric MRI * evidence for bone metastasis assessed by bone scan (if PSA \> 20 ng/ml) * WHO performance status \> 2 * previous pelvic irradiation or radical prostatectomy. * other malignancy except adequately treated basal cell carcinoma of the skin diagnosed during the last 5 years * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Work-unit 2 * serum testosterone level \<50ng/ml * symptomatic metastases * local relapse on MRI * PSA rise while on active treatment with LHRH-agonist, LHRH-antagonist, Anti-androgen, Complete androgen blockade, Oestrogen-antioestrogen therapy * previous treatment with cytotoxic agent for PCa * treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids,…) * disorder precluding understanding of trial information or informed consent